Patents Represented by Attorney, Agent or Law Firm Bozicevic, Field and Francis LLP
-
Patent number: 8139715Abstract: Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR.Type: GrantFiled: February 16, 2011Date of Patent: March 20, 2012Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Brian Kobilka, Daniel Rosenbaum
-
Patent number: 8133666Abstract: The present invention provides methods of identifying agents that reduce a level of active APOBEC3C in a cell. The present invention provides agents that reduce a level of active APOBEC3C in a cell; and compositions comprising the agents. The present invention further provides methods of reducing the mutation rate of a lentivirus in a cell; and methods of reducing the emergence of drug-resistant strains of lentivirus. The present invention further provides methods for treating lentivirus infections.Type: GrantFiled: October 31, 2005Date of Patent: March 13, 2012Assignee: The J. David Gladstone InstitutesInventors: Robert M. Grant, Khaoula Bourara
-
Patent number: 8133862Abstract: The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having insulin-like growth factor-1 deficiency (IGFD). The invention relates to methods comprising administering insulin-like growth factor-I to a patient having a height which, at the time of treatment or prior to initial treatment with IGF-1, is at least about 2 standard deviations below normal for a subject of the same age and gender, a blood level of insulin-like growth factor-I that, and at the time of treatment or prior to initial treatment with IGF-1, is below normal mean levels, usually at least about 1 standard deviations below normal mean levels, for age and gender.Type: GrantFiled: March 16, 2009Date of Patent: March 13, 2012Assignee: Tercica, Inc.Inventor: Ross G. Clark
-
Patent number: 8129365Abstract: The invention provides chromoionophore compounds comprising a triazacryptand (TAC) K+ ionophore conjugated to at least a first chromophoric moiety (e.g., xanthylium dyes and derivatives thereof). In related embodiments, the chromoionophore compounds further comprise a second chromophoric moiety which is insensitive to potassium binding by the TAC ionophore, thus providing for dual wavelength detection and absolute determination of K+ concentration. The invention further provides methods and kits for the determination of K+ concentrations in biological systems, either in vitro or in vivo, using embodiments of inventive chromoionophores.Type: GrantFiled: October 11, 2006Date of Patent: March 6, 2012Assignee: The Regents of the University of CaliforniaInventors: Alan Verkman, Prashant A. Padmawar
-
Patent number: 8123684Abstract: Techniques for controlling one or more modular circuits (“satellites”) that are intended for placement in a subject's body. The one or more satellites are controlled by sending signals over a bus that includes first and second conduction paths. Also coupled to the bus in system embodiments is a device such as a pacemaker that provides power and includes control circuitry. Each satellite includes satellite circuitry and one or more effectors that interact with the tissue. The satellite circuitry is coupled to the bus, and thus interfaces the controller to the one or more effectors, which may function as actuators, sensors, or both. The effectors may be electrodes that are used to introduce analog electrical signals (e.g., one or more pacing pulses) into the tissue in the local areas where the electrodes are positioned (e.g., heart muscles) or to sense analog signals (e.g., a propagating depolarization signal) within the tissue.Type: GrantFiled: November 23, 2009Date of Patent: February 28, 2012Assignee: Proteus Biomedical, Inc.Inventor: Mark J. Zdeblick
-
Patent number: 8124407Abstract: Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an expression cassette. Also provided are methods of using the subject vectors for introduction of a nucleic acid, e.g., an expression cassette, into a target cell, as well as preparations for use in practicing such methods. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications. Also provided is a highly efficient and readily scalable method for producing the vectors employed in the subject methods, as well as reagents and kits/systems for practicing the same.Type: GrantFiled: January 13, 2011Date of Patent: February 28, 2012Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mark A. Kay, Zhi-Ying Chen
-
Patent number: 8124389Abstract: The present disclosure provides a crystal structure of aldehyde dehydrogenase (ALDH) with a modulator of ALDH bound thereto. The present disclosure provides a computer readable medium comprising atomic coordinates for an ALDH polypeptide and a modulator bound to a site within the polypeptide. A method is also provided. In general terms, the method comprises computationally identifying a compound that binds to an ALDH polypeptide, using the atomic coordinates.Type: GrantFiled: May 4, 2009Date of Patent: February 28, 2012Assignees: The Board of Trustees of the Leland Stanford Junior University, Indiana University Research and Technology CorporationInventors: Che-Hong Chen, Daria Mochly-Rosen, Thomas D. Hurley
-
Patent number: 8124336Abstract: Aspects of the present invention are drawn to methods and compositions for sorting nucleic acid molecules into physically separate compartments according to the identity of a nucleotide base or sequence of bases at a specific location, resulting in the production of reduced complexity samples that find use in any number of downstream genetic analyses. Aspects of the methods of the invention include fragmenting a nucleic acid sample, e.g., with a restriction enzyme, ligating an adaptor (or adaptors), and sorting the fragments based on the identity of the nucleotide base(s) positioned adjacent to the fragmentation site (e.g., the restriction enzyme cut site/or recognition site). Each round of sorting produces binned samples having reduced complexity over the parent sample.Type: GrantFiled: September 23, 2008Date of Patent: February 28, 2012Assignee: Population Genetics Technologies LtdInventor: Sydney Brenner
-
Patent number: 8123929Abstract: A sensor designed to determine the amount and concentration of analyte in a sample having a volume of less than about 1 ?L. The sensor has a working electrode coated with a non-leachable redox mediator. The redox mediator acts as an electron transfer agent between the analyte and the electrode. In addition, a second electron transfer agent, such as an enzyme, can be added to facilitate the electrooxidation or electroreduction of the analyte. The redox mediator is typically a redox compound bound to a polymer. The preferred redox mediators are air-oxidizable. The amount of analyte can be determined by coulometry. One particular coulometric technique includes the measurement of the current between the working electrode and a counter or reference electrode at two or more times. The charge passed by this current to or from the analyte is correlated with the amount of analyte in the sample. Other electrochemical detection methods, such as amperometric, voltammetric, and potentiometric techniques, can also be used.Type: GrantFiled: September 29, 2009Date of Patent: February 28, 2012Assignee: Abbott Diabetes Care Inc.Inventors: Adam Heller, Benjamin J. Feldman, James Say, Mark S. Vreeke
-
Patent number: 8119156Abstract: Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.Type: GrantFiled: May 8, 2009Date of Patent: February 21, 2012Assignee: Aradigm CorporationInventors: David C. Cipolla, James Blanchard
-
Patent number: 8118992Abstract: A sensor designed to determine the amount and concentration of analyte in a sample having a volume of less than about 1 ?L. The sensor has a working electrode coated with a non-leachable redox mediator. The redox mediator acts as an electron transfer agent between the analyte and the electrode. In addition, a second electron transfer agent, such as an enzyme, can be added to facilitate the electrooxidation or electroreduction of the analyte. The redox mediator is typically a redox compound bound to a polymer. The preferred redox mediators are air-oxidizable. The amount of analyte can be determined by coulometry. One particular coulometric technique includes the measurement of the current between the working electrode and a counter or reference electrode at two or more times. The charge passed by this current to or from the analyte is correlated with the amount of analyte in the sample. Other electrochemical detection methods, such as amperometric, voltammetric, and potentiometric techniques, can also be used.Type: GrantFiled: September 29, 2009Date of Patent: February 21, 2012Assignee: Abbott Diabetes Care Inc.Inventors: Adam Heller, Benjamin J. Feldman, James Say, Mark S. Vreeke
-
Patent number: 8118993Abstract: A sensor utilizing a non-leachable or diffusible redox mediator is described. The sensor includes a sample chamber to hold a sample in electrolytic contact with a working electrode, and in at least some instances, the sensor also contains a non-leachable or a diffusible second electron transfer agent. The sensor and/or the methods used produce a sensor signal in response to the analyte that can be distinguished from a background signal caused by the mediator. The invention can be used to determine the concentration of a biomolecule, such as glucose or lactate, in a biological fluid, such as blood or serum, using techniques such as coulometry, amperometry; and potentiometry. An enzyme capable of catalyzing the electrooxidation or electroreduction of the biomolecule is typically provided as a second electron transfer agent.Type: GrantFiled: September 29, 2009Date of Patent: February 21, 2012Assignee: Abbott Diabetes Care Inc.Inventors: Benjamin J. Feldman, Adam Heller, Ephraim Heller, Fei Mao, Joseph A. Vivolo, Jeffery V. Funderburk, Fredric C. Colman, Rajesh Krishnan
-
Patent number: 8118771Abstract: A method for filling needleless injector capsules with liquid drug, whereby dissolved gas within the drug is replaced by a less soluble gas in order to reduce the inclusion of gas bubbles, or to prevent the growth of bubbles during storage and thereby prevent breakage of the capsules.Type: GrantFiled: October 29, 2007Date of Patent: February 21, 2012Assignee: Zogenix, Inc.Inventors: William Henry, Andrew Lewis
-
Patent number: 8118812Abstract: Methods of employing bone defect filling, e.g., orthopedic cements, in conjunction with hard tissue securing devices, e.g., screws, plates or rods, are provided. A feature of the subject methods is that the cement is introduced to a target bone site through a passageway of the securing device while a vibratory force is applied to the securing device. Also provided are systems and kits that find use in practicing the subject methods. The subject methods, devices and systems find use in a variety of different applications.Type: GrantFiled: October 4, 2005Date of Patent: February 21, 2012Assignee: Skeletal Kinetics, LLCInventors: Duran Yetkinler, David Delaney, Brent R. Constantz
-
Patent number: 8121690Abstract: Methods are provided for treating a subject for a fertility condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated to increase the sympathetic activity/parasympathetic activity ratio in a manner that is effective to treat the subject for the condition. Embodiments of the subject invention include modulating a subject's autonomic nervous system using electrical energy and/or one or more pharmacological agents. The subject methods find use in the treatment of a variety of different fertility conditions. Also provided are kits for use in practicing the subject methods.Type: GrantFiled: January 22, 2010Date of Patent: February 21, 2012Assignee: Palo Alto InvestorsInventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
-
Patent number: 8121687Abstract: Methods for evaluating motion of a cardiac tissue location, e.g., heart wall, are provided. In the subject methods, timing of a signal obtain from a strain gauge stably associated with the tissue location of interest is employed to evaluate movement of the cardiac tissue location. Also provided are systems, devices and related compositions for practicing the subject methods. The subject methods and devices find use in a variety of different applications, including cardiac resynchronization therapy.Type: GrantFiled: October 31, 2005Date of Patent: February 21, 2012Assignee: Proteus Biomedical, Inc.Inventors: Marc Jensen, Todd Thompson, Olivier Colliou, George M. Savage, Mark J. Zdeblick, Jeremy Frank, Lawrence W. Arne, Robert White
-
Patent number: 8119125Abstract: Methods and compositions are provided for stabilizing polypeptides for oral administration, particularly where enteric delivery is desirable. By administering the polypeptides with a bile sequestering agent, the stability of the polypeptide can be increased. Pharmaceutical formulations for this purpose are provided.Type: GrantFiled: October 11, 2006Date of Patent: February 21, 2012Assignee: Alvine Pharmaceuticals, Inc.Inventor: Jonathan David Gass
-
Patent number: 8115618Abstract: RFID antennas for ingestible devices, such as ingestible event markers, are provided. Aspects of the ingestible devices of the invention include RFID signal transmission antennas with a battery that is activated upon being exposed to fluid in the body. Embodiments of the RFID antennas are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the devices of the invention.Type: GrantFiled: May 23, 2008Date of Patent: February 14, 2012Assignee: Proteus Biomedical, Inc.Inventors: Timothy L. Robertson, Olivier Colliou, Eric J. Snyder, Mark J. Zdeblick
-
Patent number: 8114270Abstract: A sensor designed to determine the amount and concentration of analyte in a sample having a volume of less than about 1 ?L. The sensor has a working electrode coated with a non-leachable redox mediator. The redox mediator acts as an electron transfer agent between the analyte and the electrode. In addition, a second electron transfer agent, such as an enzyme, can be added to facilitate the electrooxidation or electroreduction of the analyte. The redox mediator is typically a redox compound bound to a polymer. The preferred redox mediators are air-oxidizable. The amount of analyte can be determined by coulometry. One particular coulometric technique includes the measurement of the current between the working electrode and a counter or reference electrode at two or more times. The charge passed by this current to or from the analyte is correlated with the amount of analyte in the sample. Other electrochemical detection methods, such as amperometric, voltammetric, and potentiometric techniques, can also be used.Type: GrantFiled: February 7, 2008Date of Patent: February 14, 2012Assignee: Abbott Diabetes Care Inc.Inventors: Adam Heller, Benjamin J. Feldman, James Say, Mark S. Vreeke
-
Patent number: 8114271Abstract: A sensor designed to determine the amount and concentration of analyte in a sample having a volume of less than about 1 ?L. The sensor has a working electrode coated with a non-leachable redox mediator. The redox mediator acts as an electron transfer agent between the analyte and the electrode. In addition, a second electron transfer agent, such as an enzyme, can be added to facilitate the electrooxidation or electroreduction of the analyte. The redox mediator is typically a redox compound bound to a polymer. The preferred redox mediators are air-oxidizable. The amount of analyte can be determined by coulometry. One particular coulometric technique includes the measurement of the current between the working electrode and a counter or reference electrode at two or more times. The charge passed by this current to or from the analyte is correlated with the amount of analyte in the sample. Other electrochemical detection methods, such as amperometric, voltammetric, and potentiometric techniques, can also be used.Type: GrantFiled: September 29, 2009Date of Patent: February 14, 2012Assignee: Abbott Diabetes Care Inc.Inventors: Adam Heller, Benjamin J. Feldman, James Say, Mark S. Vreeke